Table 2 Characteristics of the 66 infectious episodes that led to linezolid prescription in the study NICU (2010–2019)
n (%) | |
|---|---|
Age at first symptoms (days)a | 20 (9;33) |
Hemodynamic instability | 28 (42%) |
Strains | |
Staphylococcus epidermidis | 23 (35%) |
Staphylococcus capitis | 11 (17%) |
Staphylococcus aureus | 9 (14%) |
Staphylococcus haemolyticus | 3 (5%) |
Enterobacter cloacae | 1 (2%) |
Staphylococcus gallinarum | 1 (2%) |
No identification (clinical sepsis) | 7 (11%) |
Polymicrobial | 11 (17%) |
Resistance to vancomycin | 2 (3%) |
Site of infection | |
All bacteremia | 39 (59%) |
Including persistent bacteremia | 25 (64%) |
Isolated bacteremia | 32 (48%) |
Pneumoniae | 23 (35%) |
Other (CSF, peritoneal fluid) | 4 (6%) |
No identification (clinical sepsis) | 7 (11%) |
First-line treatment | |
Vancomycin | 51 (77%) |
Linezolid | 12 (18%) |
Other | 3 (5%) |
Antibiotic association (≥ 2 antibiotics) | 46 (70%) |
including amikacin | 43 (93%) |
Delay before linezolid use (days)a | 3 (2;6) |
Linezolid treatment duration (days)a | 7 (3;10) |
Central line removal | 25 (38%) |
In case of persistent bacteremia | 21 (88%) |